<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1178</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">5</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2026</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">26</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.residualCancerBurdenRCB<br/><br/>

<div class='content chap10-para-head'><strong>Description</strong></div>
<div class='content chap10-para'>
<p>Residual Cancer Burden (RCB) is a score that measures the amount of cancer remaining in the breast and the regional lymph nodes after neoadjuvant therapy and surgical resection. The RCB score is based on 4 independent prognostic factors measuring the primary tumor bed and 2 independent factors measuring the lymph nodes. </p>
<p>The RCB score combines these 6 independently prognostic factors from the surgical specimen after neoadjuvant therapy into a single continuous score. This score is prognostic across breast cancer subtypes, different treatments, and within existing stage groups. </p>
<p>The independent prognostic factors include</p>
<ol>
<li>Primary Tumor Bed
<ol>
<li>Primary Tumor Bed area (measured in millimeters)
<ol>
<li>Includes the largest two dimensions</li>
</ol>
</li>
<li>Overall Cancer Cellularity (as percentage of area)</li>
<li>Percentage of cancer that is invasive disease</li>
<li>Percentage of cancer that is in situ disease</li>
</ol>
</li>
<li>Lymph nodes
<ol>
<li>Number of positive lymph nodes</li>
<li>Diameter of largest metastasis</li>
</ol>
</li>
</ol>

</div>

<div class='content chap10-para-head'><strong>Rationale</strong></div>
<div class='content chap10-para'>
<p>Neoadjuvant therapy is now standard of care for HER2+ and triple negative breast carcinoma. Quantification of residual disease after neoadjuvant therapy determines further patient management in this setting. The Residual Cancer Burden (RCB) is the most validated measure of volume of residual disease post neoadjuvant for breast cancer and has prognostic value.</p>

</div>



<div class='content chap10-para'><strong>Codes</strong></div>
<table>
        <tr class='code-row'><td class='code-nbr'>0.000-9.999</td><td class='code-desc'>0.000 – 9.999 score</td></tr>
        <tr class='code-row'><td class='code-nbr'>X.777</td><td class='code-desc'>Patient had neoadjuvant therapy, but not a post neoadjuvant surgical resection.

Patient did not have neoadjuvant therapy.</td></tr>
        <tr class='code-row'><td class='code-nbr'>X.888</td><td class='code-desc'>Not applicable: information not collected for this case (If this item is required by your standard setter, use of code X.8 will result in an edit error).</td></tr>
        <tr class='code-row'><td class='code-nbr'>X.999</td><td class='code-desc'>Post neoadjuvant surgery completed and RCB burden not documented in CAP Protocol or synoptic pathology report.

Post neoadjuvant surgery completed and surgical pathology report not available.</td></tr>
        <tr class='code-row'><td class='code-nbr'>Blank</td><td class='code-desc'>Must be blank if diagnosis year is before 2026.</td></tr>
</table>

